PET/CT for Trop2 ADC Response Evaluation NSCLC

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY ·

Keywords

ClinConnect Summary

This clinical trial is studying a new way to see how well a treatment works for people with a type of lung cancer called non-small cell lung cancer (NSCLC). The treatment uses a special drug that targets a protein called Trop2 on cancer cells. To check if the treatment is working, doctors will use a special imaging test called PET/CT scans with a marker named 68Ga-MY6349. These scans are done over time to help predict how well the treatment is helping to fight the cancer without needing more invasive tests.

People who may be eligible to join are adults between about 65 and 74 years old who have NSCLC and are being treated with this Trop2-targeted therapy. Both men and women can participate. If you join the study, you can expect to have several PET/CT scans during your treatment to monitor how your cancer is responding. This trial is currently recruiting participants, and it aims to find an easier and less invasive way to see if the treatment is effective, which could help doctors make better decisions about care in the future.

Gender

ALL

Eligibility criteria